Supplementary Table 2. Clinicopathological characteristics of patients by different markers

	CD4$^+$ cell		CD8$^+$ cell		Foxp3$^+$ cell		PD-1		PD-L1	
	Absent	Infiltration	Absent	Infiltration	Absent	Infiltration	Positive	Negative	Positive	Negativ
	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
Gender	304	263	404	167	337	222	234	337	170	352
Male	225 (74.0)	180 (68.4)	289 (71.5)	118 (70.7)	237 (70.3)	162 (73.0)	170 (72.6)	237 (70.3)	119 (70.0)	251 (71.
Female	79 (26.0)	83 (31.6)	115 (28.5)	49 (29.3)	100 (29.7)	60 (27.0)	64 (27.4)	100 (29.7)	51 (30.0)	101 (28.
Age (year)	304	263	404	167	337	222	234	337	170	352
Median	29-86 (59)	21-87 (58)	28-82 (58)	21-87 (58)	28-87 (58)	21-86 (59)	21-87 (59)	28-87 (58)	26-87 (58)	21-86 (5
AJCC	286	262	387	165	330	210	223	329	165	338
Ia	4 (1.4)	10 (3.8)	8 (2.1)	6 (3.6)	4 (1.2)	9 (4.3)	4 (1.8)	10 (3.0)	4 (2.4)	8 (2.4)
Ib	12 (4.2)	20 (7.6)	15 (3.9)	17 (10.3)	10 (3.0)	22 (10.5)	13 (5.8)	19 (5.8)	15 (9.1)	14 (4.1
IIa	19 (6.6)	34 (13.0)	38 (9.8)	17 (10.3)	24 (7.3)	30 (14.3)	18 (8.1)	37 (11.2)	13 (7.9)	33 (9.8
IIb	44 (15.4)	50 (19.1)	64 (16.5)	31 (18.8)	55 (16.7)	38 (18.1)	34 (15.2)	61 (18.5)	27 (16.4)	61 (18.
IIIa	52 (18.2)	45 (17.2)	64 (16.5)	34 (20.6)	61 (18.5)	35 (16.7)	45 (20.2)	53 (16.1)	21 (12.7)	71 (21.
IIIb	80 (26.3)	58 (22.1)	110 (28.4)	28 (17.0)	91 (27.6)	46 (21.9)	55 (14.7)	83 (25.2)	47 (28.5)	79 (23.
IIIc	56 (19.6)	33 (12.6)	62 (16.0)	27 (16.4)	60 (17.8)	26 (12.4)	44 (19.7)	45 (13.7)	32 (19.4)	51 (15.
IV	19 (6.6)	12 (4.6)	26 (6.7)	5 (3.0)	25 (7.6)	4 (1.9)	10 (4.5)	21 (6.4)	6 (3.6)	21 (6.2

	270	255	371	158	314	204	216	313	158	323
Location										
Upper 1/3	80 (29.6)	102 (40.0)	121 (32.6)	63 (39.9)	113 (36.0)	68 (33.3)	68 (31.5)	116 (37.1)	57 (36.1)	114 (35.
Middle 1/3	37 (13.7)	46 (18.0)	62 (16.7)	22 (13.9)	44 (14.0)	39 (19.1)	47 (21.8)	37 (11.8)	27 (17.1)	41 (12.
Lower 1/3	122 (45.2)	88 (34.5)	152 (41.0)	59 (37.3)	120 (38.2)	85 (41.7)	85 (39.4)	126 (40.3)	61 (38.6)	134 (41.
Upper 1/3 and whole	29 (10.8)	18 (7.1)	33 (8.9)	14 (8.9)	34 (10.8)	12 (5.9)	14 (6.5)	33 (10.6)	13 (8.3)	31 (9.6
Remnant	2 (0.7)	1 (0.4)	3 (0.8)	0	3 (1.0)	0	2 (0.9)	1 (0.3)	0	3 (0.9)
Depth	301	261	401	165	335	219	233	333	168	349
Mucosa	1 (0.3)	2 (0.8)	1 (0.2)	2 (1.2)	1 (0.3)	2 (0.9)	0	3 (0.9)	1 (0.6)	2 (0.6)
Laminae muscularis mucosae	0	1 (0.4)	0	1 (0.6)	1 (0.3)	0	0	1 (0.3)	1 (0.6)	0
Submucosa	4 (1.3)	11 (4.2)	11 (2.7)	4 (2.4)	6 (1.8)	8 (3.7)	5 (2.1)	10 (3.0)	5 (3.0)	7 (2.0)
Muscular	23 (7.6)	39 (14.9)	40 (10.0)	23 (13.9)	23 (6.9)	38 (17.4)	28 (12.0)	35 (10.5)	23 (13.7)	36 (10.
Serosa	151 (50.2)	142 (54.4)	215 (53.6)	79 (47.9)	171 (51.0)	122 (55.7)	129 (55.4)	165 (49.5)	78 (46.4)	183 (52.
Subserosa	122 (40.5)	66 (25.3)	134 (33.4)	56 (33.9)	133 (39.7)	49 (22.4)	71 (30.5)	119 (35.7)	60 (35.7)	121 (34.

Abbreviations: CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; Foxp3, Forkhead box P3; PD-1, programmed death 1; PD-L1, programmed death ligand-1; N, number; AJCC, American Joint Committee on Cancer